DT Cloud Acquisition Corp. Updates on Maius Pharmaceutical Merger, Announces $150,000 Private Placement with Pubco

Reuters
Oct 01
DT Cloud Acquisition Corp. Updates on Maius Pharmaceutical Merger, Announces $150,000 Private Placement with Pubco

DT Cloud Acquisition Corp. announced an update regarding its previously disclosed business combination with Maius Pharmaceutical Co., Ltd. According to a recent filing, DT Cloud Acquisition Corp. has entered into a Subscription Agreement with Maius, Pubco, and an investor. Under this agreement, the investor will purchase 15,000 ordinary shares of Pubco at $10.00 per share in a private placement. The completion of this private placement is contingent on the closing of the broader business combination transaction involving DT Cloud Acquisition Corp., Maius, and related entities. The company stated that these steps are part of its ongoing efforts to finalize the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DT Cloud Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-016335), on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10